NF-kappa B Inhibitors Clinical Trial Pipeline Analysis: 10+ Key Companies Shaping the Future of NF-kappa B Inhibitors Therapeutics | DelveInsight

DelveInsight's NF-kappa B Inhibitors Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline NF-kappa B Inhibitors therapies in various stages of clinical development. The report provides insights into 10+ companies and 12+ pipeline drugs in the NF-kappa B Inhibitors pipeline landscape, covering clinical and nonclinical stage products, therapeutic assessments, and inactive pipeline products.

Key takeaways from the NF-kappa B Inhibitors Clinical Trial Landscape Report

• DelveInsight's NF-kappa B Inhibitors pipeline report depicts a developing space with 10+ companies working to develop 12+ pipeline therapies for NF-kappa B Inhibitors.
• Key NF-kappa B Inhibitors companies such as BioVie, Inc., Yiviva, Ilias Bio, SFA THERAPEUTICS, INC., EntreChem, and others.
• Promising NF-kappa B Inhibitors pipeline therapies in various stages of development include NE3107, YIV-906, ILB-202, SFA 001, EC-70124, and others.

Request a sample and discover the recent advances in NF-kappa B Inhibitors therapies https://www.delveinsight.com/sample-request/nf-kappa-b-inhibitors-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

What are NF-kappa B Inhibitors?

NF-κB inhibitors are agents that suppress the activity of the NF-κB family of transcription factors, which are central regulators of inflammation, immunity, cell survival, and proliferation. NF-κB comprises a family of related proteins, including RelA (p65), RelB, c-Rel, p50, and p52, which form various heterodimers.
NF-κB signaling is primarily mediated through canonical and non-canonical pathways. The canonical pathway involves activation of the IκB kinase complex, degradation of IκB, and nuclear translocation of NF-κB dimers, while the non-canonical pathway involves NF-κB-inducing kinase and IKKα.
NF-κB inhibitors play a significant role in disease management by attenuating aberrant NF-κB activation and pathological gene expression. In inflammatory and autoimmune disorders such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease, NF-κB inhibition can reduce cytokine production and immune cell activation. In cancer, NF-κB inhibition may suppress tumor cell survival, proliferation, angiogenesis, and resistance to apoptosis. NF-κB inhibitors are also being explored in neurodegenerative, cardiovascular, and metabolic diseases.

Emerging NF-kappa B Inhibitors Drug Profiles

NE3107: BioVie Inc.
NE3107 is an orally bioavailable, blood-brain barrier-permeable, insulin-sensitizer that also possesses anti-inflammatory properties. It is not immunosuppressive and has a low risk of drug-to-drug interaction. NE3107 has the potential to reduce symptoms of long COVID, including fatigue and cognitive dysfunction. Persistently circulating viral spike proteins are believed to trigger TLR-4-driven activation of NF-κB and subsequent expression of inflammatory cytokines. NE3107 has been shown to modulate NF-κB activation and inflammation. It is also being investigated for Alzheimer's disease and Parkinson's disease. Currently, the drug is in Phase III clinical development for Alzheimer's disease.

YIV-906: Yiviva
YIV-906, formerly known as PHY906 or KD018, is a patented, orally administered investigational drug that acts as a pan-adjuvant designed to improve the efficacy and safety of a broad spectrum of cancer drugs and treatment regimens, including chemotherapy, immunotherapy, radiation, and cell therapies.
YIV-906 has been studied in clinical trials involving solid tumors, including hepatocellular carcinoma, pancreatic cancer, colorectal cancer, and rectal cancer. The therapy has demonstrated potential to improve overall survival and/or progression-free survival while reducing non-hematological toxicities. The FDA has granted YIV-906 two Orphan Drug Designations for hepatocellular carcinoma and pancreatic cancer. Currently, the drug is in the Phase II stage of clinical development for advanced hepatocellular carcinoma and colorectal cancer.

ILB-202: Ilias Bio
ILB-202 is an engineered exosome therapeutic containing the anti-inflammatory protein super-repressor IκB (srlκB), designed to inhibit NF-κB translocation into the nucleus and thereby reduce inflammatory responses. Developed by ILIAS Biologics, ILB-202 directly targets core cytosolic inflammation signaling and may offer fewer off-target effects than conventional upstream pathway inhibitors.
ILB-202 has undergone Phase I clinical trials evaluating safety and tolerability in healthy volunteers, particularly for conditions such as acute kidney injury associated with cardiac surgery.

Learn more about the novel and emerging NF-kappa B Inhibitors pipeline therapies https://www.delveinsight.com/sample-request/nf-kappa-b-inhibitors-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Scope of the NF-kappa B Inhibitors Pipeline Report

• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Phase III, Phase II, Phase I, Preclinical, Discovery
• Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical
• Therapeutics Assessment By Molecule Type: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy
• Key NF-kappa B Inhibitors Companies: BioVie, Inc., Yiviva, Ilias Bio, SFA THERAPEUTICS, INC., EntreChem
• Key NF-kappa B Inhibitors Pipeline Therapies: NE3107, YIV-906, ILB-202, SFA 001, EC-70124

Dive deep into rich insights for emerging NF-kappa B Inhibitors therapies, visit https://www.delveinsight.com/sample-request/nf-kappa-b-inhibitors-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents

1. NF-kappa B Inhibitors Pipeline Report Introduction
2. NF-kappa B Inhibitors Pipeline Report Executive Summary
3. NF-kappa B Inhibitors: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. NF-kappa B Inhibitors Pipeline Therapeutics
6. NF-kappa B Inhibitors Pipeline: Late Stage Products (Phase III)
7. NF-kappa B Inhibitors Pipeline: Mid Stage Products (Phase II)
8. NF-kappa B Inhibitors Pipeline: Early Stage Products (Phase I)
9. NF-kappa B Inhibitors Pipeline: Preclinical and Discovery Stage Products
10. NF-kappa B Inhibitors Pipeline Therapeutics Assessment
11. Inactive Products in the NF-kappa B Inhibitors Pipeline
12. Key Companies
13. Key Products in the NF-kappa B Inhibitors Pipeline
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

For further information on the NF-kappa B Inhibitors pipeline therapeutics, reach out https://www.delveinsight.com/sample-request/nf-kappa-b-inhibitors-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Media Contact
Company Name: DelveInsight
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +1-469-945-7679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.